391 related articles for article (PubMed ID: 18332901)
21. Lactate dehydrogenase is a prognostic indicator for prostate cancer patients with bone metastasis.
Naruse K; Yamada Y; Aoki S; Taki T; Nakamura K; Tobiume M; Zennami K; Katsuda R; Sai S; Nishio Y; Inoue Y; Noguchi H; Hondai N
Hinyokika Kiyo; 2007 May; 53(5):287-92. PubMed ID: 17561711
[TBL] [Abstract][Full Text] [Related]
22. Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers.
Leeming DJ; Hegele A; Byrjalsen I; Hofmann R; Qvist P; Karsdal MA; Schrader AJ; Wagner R; Olbert P
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1269-76. PubMed ID: 18483350
[TBL] [Abstract][Full Text] [Related]
23. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
[TBL] [Abstract][Full Text] [Related]
24. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases.
Selander KS; Brown DA; Sequeiros GB; Hunter M; Desmond R; Parpala T; Risteli J; Breit SN; Jukkola-Vuorinen A
Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):532-7. PubMed ID: 17372249
[TBL] [Abstract][Full Text] [Related]
25. Is neuroendocrine cell differentiation detected using chromogranin A from patients with bone metastatic prostate cancer a prognostic factor for outcome?
Yamada Y; Nakamura K; Aoki S; Taki T; Matsubara H; Sai S; Naruse K; Tobiume M; Katsuda R; Zennami K; Honda N; Nakagawa A; Ikeda H
Oncol Rep; 2006 May; 15(5):1309-13. PubMed ID: 16596203
[TBL] [Abstract][Full Text] [Related]
26. Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications.
Tumminello FM; Flandina C; Crescimanno M; Leto G
Biomed Pharmacother; 2008 Feb; 62(2):130-5. PubMed ID: 17728092
[TBL] [Abstract][Full Text] [Related]
27. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
Palma D; Tyldesley S; Pickles T;
Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814
[TBL] [Abstract][Full Text] [Related]
28. The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load.
Generali D; Berruti A; Tampellini M; Dovio A; Tedoldi S; Bonardi S; Tucci M; Allevi G; Aguggini S; Milani M; Bottini A; Dogliotti L; Angeli A
Bone; 2007 Jan; 40(1):182-8. PubMed ID: 16935041
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcome of gastric cancer patients with bone marrow metastases.
Kim HS; Yi SY; Jun HJ; Lee J; Park JO; Park YS; Jang J; Kim HJ; Ko Y; Lim HY; Kang WK
Oncology; 2007; 73(3-4):192-7. PubMed ID: 18418012
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy.
Sekine I; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T
Lung Cancer; 2009 Aug; 65(2):219-22. PubMed ID: 19081161
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of global grading system of Gleason score in patients with prostate cancer with bone metastasis.
Kambara T; Oyama T; Segawa A; Fukabori Y; Yoshida K
BJU Int; 2010 Jun; 105(11):1519-25. PubMed ID: 19912185
[TBL] [Abstract][Full Text] [Related]
32. Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival.
Daneshmand S; Quek ML; Lin E; Lee C; Cote RJ; Hawes D; Cai J; Groshen S; Lieskovsky G; Skinner DG; Lee AS; Pinski J
Hum Pathol; 2007 Oct; 38(10):1547-52. PubMed ID: 17640713
[TBL] [Abstract][Full Text] [Related]
33. [Relationship of neuroendocrine differentiation to biological behavior of prostate cancer].
Wu XL; Huang KT; Chen W; Chen L; Dong L; Yu ZX
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):472-5. PubMed ID: 19567097
[TBL] [Abstract][Full Text] [Related]
34. Stimulation of calcium reabsorption observed in advanced breast cancer patients with hypercalcemia and multiple bone metastases.
Kimura S; Adchi I; Yamaguchi K; Suzuki M; Shimada A; Sato Y; Nagaoka K; Abe K
Jpn J Cancer Res; 1985 Apr; 76(4):308-14. PubMed ID: 2989061
[TBL] [Abstract][Full Text] [Related]
35. Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates.
Berruti A; Dogliotti L; Tucci M; Tarabuzzi R; Fontana D; Angeli A
J Urol; 2001 Dec; 166(6):2023-31. PubMed ID: 11696699
[TBL] [Abstract][Full Text] [Related]
36. [Clinical evaluation on serum osteocalcin in advanced prostate cancer patients].
Abe H; Nakagami YJ; Ito H; Ikeda K; Oka F; Niwa N
Hinyokika Kiyo; 1991 Aug; 37(8):877-80. PubMed ID: 1720275
[TBL] [Abstract][Full Text] [Related]
37. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer.
Danila DC; Heller G; Gignac GA; Gonzalez-Espinoza R; Anand A; Tanaka E; Lilja H; Schwartz L; Larson S; Fleisher M; Scher HI
Clin Cancer Res; 2007 Dec; 13(23):7053-8. PubMed ID: 18056182
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer.
Nishio Y; Yamada Y; Kokubo H; Nakamura K; Aoki S; Taki T; Honda N; Nakagawa A; Saga S; Hara K
Urology; 2006 Jul; 68(1):110-5. PubMed ID: 16806433
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data.
Mountzios G; Ramfidis V; Terpos E; Syrigos KN
Clin Lung Cancer; 2011 Nov; 12(6):341-9. PubMed ID: 21703936
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2009 Mar; 181(3):1091-7. PubMed ID: 19150091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]